{"title":"Epidermal RAF prevents allergic skin disease","author":[{"surname":"Raguz","given-names":"Josipa"},{"surname":"Jeric","given-names":"Ines"},{"surname":"Niault","given-names":"Theodora"},{"surname":"Nowacka","given-names":"Joanna Daniela"},{"surname":"Kuzet","given-names":"Sanya Eduarda"},{"surname":"Rupp","given-names":"Christian"},{"surname":"Fischer","given-names":"Irmgard"},{"surname":"Biggi","given-names":"Silvia"},{"surname":"Borsello","given-names":"Tiziana"},{"surname":"Baccarini","given-names":"Manuela"}],"abstract":"The RAS pathway is central to epidermal homeostasis, and its activation in tumors or in Rasopathies correlates with hyperproliferation. Downstream of RAS, RAF kinases are actionable targets regulating keratinocyte turnover; however, chemical RAF inhibitors paradoxically activate the pathway, promoting epidermal proliferation. We generated mice with compound epidermis-restricted BRAF/RAF1 ablation. In these animals, transient barrier defects and production of chemokines and Th2-type cytokines by keratinocytes cause a disease akin to human atopic dermatitis, characterized by IgE responses and local and systemic inflammation. Mechanistically, BRAF and RAF1 operate independently to balance MAPK signaling: BRAF promotes ERK activation, while RAF1 dims stress kinase activation. In vivo, JNK inhibition prevents disease onset, while MEK/ERK inhibition in mice lacking epidermal RAF1 phenocopies it. These results support a primary role of keratinocytes in the pathogenesis of atopic dermatitis, and the animals lacking BRAF and RAF1 in the epidermis represent a useful model for this disease.","identifier":[{"type":"publisher-id","id":"14012"},{"type":"doi","id":"10.7554/eLife.14012"}],"date":{"day":"19","month":"07","year":"2016"},"license":"http://creativecommons.org/licenses/by/4.0/","path":"14012","entryfile":"elife-14012-v3.xml","files":["elife-14012-fig1-figsupp1-v1-600w.jpg","elife-14012-fig1-figsupp1-v2-600w.jpg","elife-14012-fig1-figsupp1-v3-600w.jpg","elife-14012-fig1-v1-600w.jpg","elife-14012-fig1-v2-600w.jpg","elife-14012-fig1-v3-600w.jpg","elife-14012-fig10-v1-600w.jpg","elife-14012-fig10-v2-600w.jpg","elife-14012-fig10-v3-600w.jpg","elife-14012-fig2-v1-600w.jpg","elife-14012-fig2-v2-600w.jpg","elife-14012-fig2-v3-600w.jpg","elife-14012-fig3-figsupp1-v1-600w.jpg","elife-14012-fig3-figsupp1-v2-600w.jpg","elife-14012-fig3-figsupp1-v3-600w.jpg","elife-14012-fig3-v1-600w.jpg","elife-14012-fig3-v2-600w.jpg","elife-14012-fig3-v3-600w.jpg","elife-14012-fig4-figsupp1-v1-600w.jpg","elife-14012-fig4-figsupp1-v2-600w.jpg","elife-14012-fig4-figsupp1-v3-600w.jpg","elife-14012-fig4-v1-600w.jpg","elife-14012-fig4-v2-600w.jpg","elife-14012-fig4-v3-600w.jpg","elife-14012-fig5-figsupp1-v1-600w.jpg","elife-14012-fig5-figsupp1-v2-600w.jpg","elife-14012-fig5-figsupp1-v3-600w.jpg","elife-14012-fig5-v1-600w.jpg","elife-14012-fig5-v2-600w.jpg","elife-14012-fig5-v3-600w.jpg","elife-14012-fig6-v1-600w.jpg","elife-14012-fig6-v2-600w.jpg","elife-14012-fig6-v3-600w.jpg","elife-14012-fig7-figsupp1-v1-600w.jpg","elife-14012-fig7-figsupp1-v2-600w.jpg","elife-14012-fig7-figsupp1-v3-600w.jpg","elife-14012-fig7-v1-600w.jpg","elife-14012-fig7-v2-600w.jpg","elife-14012-fig7-v3-600w.jpg","elife-14012-fig8-figsupp1-v1-600w.jpg","elife-14012-fig8-figsupp1-v2-600w.jpg","elife-14012-fig8-figsupp1-v3-600w.jpg","elife-14012-fig8-figsupp2-v1-600w.jpg","elife-14012-fig8-figsupp2-v2-600w.jpg","elife-14012-fig8-figsupp2-v3-600w.jpg","elife-14012-fig8-v1-600w.jpg","elife-14012-fig8-v2-600w.jpg","elife-14012-fig8-v3-600w.jpg","elife-14012-fig9-figsupp1-v1-600w.jpg","elife-14012-fig9-figsupp1-v2-600w.jpg","elife-14012-fig9-figsupp1-v3-600w.jpg","elife-14012-fig9-v1-600w.jpg","elife-14012-fig9-v2-600w.jpg","elife-14012-fig9-v3-600w.jpg","elife-14012-v1.xml","elife-14012-v2.xml"]}